Interpace Biosciences Q4 2022 Earnings Report Earnings History Interpace Biosciences EPS ResultsActual EPS-$0.33Consensus EPS -$0.07Beat/MissMissed by -$0.26One Year Ago EPSN/AInterpace Biosciences Revenue ResultsActual Revenue$8.33 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInterpace Biosciences Announcement DetailsQuarterQ4 2022Date3/29/2023TimeQ4 2022 Earnings ReleaseConference Call ResourcesIDXG Earnings History Interpace Biosciences Earnings HeadlinesFixed Income Looks Undervalued - Cash In With 13%-Yielding PDIFebruary 14, 2025 | seekingalpha.comPDI: Buy For The Yield And FlexibilityFebruary 12, 2025 | seekingalpha.comYour trading day could end at 11 AMWhat do you usually do between 9:35 AM and 11:00 AM? Catch up on emails? Attend a meeting? Maybe grab a coffee? For me, it's become the most important part of my trading day. 85 minutes. That's usually all it takes. Set up at 9:35 AM… Check back at 11:00 AM. And when things work out, there's an extra $100 to $150 in my account… on a $1000 starting stake. Sounds too simple, doesn't it?February 23, 2025 | ProsperityPub (Ad)PDI's Yield Exceeding 13% Still Looks Inexpensive As Shares Continue HigherFebruary 12, 2025 | seekingalpha.comSPDI Transfers Ukrainian Property to Arcona Fund, Strengthening Market PositionFebruary 6, 2025 | tipranks.comPDI: Buy For A Double-Digit Yield And You May Even Beat The S&P 500February 5, 2025 | seekingalpha.comSee More Interpace Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Interpace Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Interpace Biosciences and other key companies, straight to your email. Email Address About Interpace BiosciencesInterpace Biosciences (NASDAQ:IDXG) provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.View Interpace Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)ONEOK (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Home Depot (2/25/2025)Public Storage (2/25/2025)Sempra (2/25/2025)NVIDIA (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
